Literature DB >> 11094152

Involvement of the p38 mitogen-activated protein kinase pathway in tissue inhibitor of metalloproteinases-1-induced erythroid differentiation.

E Petitfrère1, Z Kadri, C Boudot, M L Sowa, P Mayeux, B Haye, C Billat.   

Abstract

We examined the role of the mitogen-activated protein (MAP) kinase pathway in tissue inhibitor of metalloproteinases-1 (TIMP-1)-mediated cellular effects in a human erythroleukemic cell line UT-7. We show that TIMP-1 induced both UT-7 cell erythroid differentiation and proliferation and tyrosine phosphorylation of many intracellular proteins. Using a panel of phosphospecific antibodies, we also demonstrate that phosphorylation of the p38 and c-Jun N-terminal kinases is increased by TIMP-1 whereas phosphorylation of extracellular signal-regulated kinase 1/2 is not induced. Moreover, inhibition of the p38 activity by SB203580 significantly reduces erythroid differentiation induced by TIMP-1, suggesting that the p38 MAP kinase pathway is involved in TIMP-1-induced erythroid differentiation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11094152     DOI: 10.1016/s0014-5793(00)02210-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  3 in total

Review 1.  Cytokine functions of TIMP-1.

Authors:  Christian Ries
Journal:  Cell Mol Life Sci       Date:  2013-08-28       Impact factor: 9.261

2.  Tissue inhibitor of metalloproteinases-1 signalling pathway leading to erythroid cell survival.

Authors:  Elise Lambert; Cédric Boudot; Zahra Kadri; Mahdhia Soula-Rothhut; Marie-Line Sowa; Patrick Mayeux; William Hornebeck; Bernard Haye; Emmanuelle Petitfrere
Journal:  Biochem J       Date:  2003-06-15       Impact factor: 3.857

3.  Growth-stimulatory activity of TIMP-2 is mediated through c-Src activation followed by activation of FAK, PI3-kinase/AKT, and ERK1/2 independent of MMP inhibition in lung adenocarcinoma cells.

Authors:  Han Ie Kim; Hyun-Sung Lee; Tae Hyun Kim; Ju-Seog Lee; Seung-Taek Lee; Seo-Jin Lee
Journal:  Oncotarget       Date:  2015-12-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.